XML 62 R37.htm IDEA: XBRL DOCUMENT v3.25.4
PRODUCT REVENUE AND PROVISIONS FOR VARIABLE CONSIDERATION (Tables)
 12 Months Ended
Dec. 31, 2025
Revenue from Contract with Customer [Abstract]  
Schedule of Product Revenues The following table presents net product revenue for Vafseo and Auryxia (in thousands): 
Years Ended December 31,
Product202520242023
Vafseo$45,790 $— $— 
Auryxia(1)
181,542 152,180 170,301 
Total product revenues$227,332 $152,180 $170,301 
(1) Includes the authorized generic version of Auryxia sold and distributed by the Company's authorized generic distribution partner, Mylan Therapeutics, Inc., or AG Distributor, during the year ended December 31, 2025.
Schedule of Changes in Contract Assets and Liabilities
The following table presents changes in the Company’s contract assets and liabilities related to the Company's sales to its AG Distributor (in thousands):
Year Ended December 31, 2025
Balance at
Beginning of
Period		AdditionsDeductionsBalance at End
of Period
Contract assets:
Accounts receivable$— $12,006 $(11,812)$194 
Contract liabilities:
Deferred revenue$— $10,675 $(7,994)$2,681 
The following table presents changes in the Company’s contract assets and liabilities related to license, collaboration and other revenue agreements (in thousands):
Year Ended December 31, 2025
 Balance at
Beginning of
Period		AdditionsDeductionsBalance at End
of Period
Contract assets:    
Accounts receivable(1)
$2,010 $8,894 $(8,513)$2,391 
Contract liability:
Deferred revenue $— $— $— $— 
Year Ended December 31, 2024
Balance at
Beginning of
Period		AdditionsDeductionsBalance at End
of Period
Contract assets:
Accounts receivable(1)
$3,333 $8,562 $(9,885)$2,010 
Contract liabilities:
Deferred revenue (long-term)(2)
$43,296 $— $(43,296)$— 
(1)Excludes accounts receivable from product sales of Auryxia and Vafseo which are included in the accompanying consolidated balance sheets as of December 31, 2025 and 2024. 
(2)See Note 8, Liability Related to Settlement Royalties, Working Capital Fund Liability and Liability Related to Sale of Future Royalties, for further information.
Schedule of Product Revenue Allowance and Provision Categories
Product revenue allowance and provision categories were as follows:
(in thousands)Chargebacks
and
Discounts		Rebates, Fees
and other
Deductions		ReturnsTotal
Balance at December 31, 2022$1,259 $26,252 $10,923 $38,434 
Provisions related to sales in current year11,138 79,648 6,181 $96,967 
Adjustments related to prior year sales(304)(1,506)1,648 $(162)
Credits/payments made(10,486)(81,403)(11,836)$(103,725)
Balance at December 31, 2023$1,607 $22,991 $6,916 $31,514 
Current provisions related to sales in current year9,225 44,914 4,862 59,001 
Adjustments related to prior year sales(94)(2,056)(540)(2,690)
Credits/payments made(9,302)(50,123)(4,796)(64,221)
Balance at December 31, 2024$1,436 $15,726 $6,442 $23,604 
Current provisions related to sales in current year4,051 81,019 634 85,704 
Adjustments related to prior year sales69 143 (1,631)(1,419)
Credits/payments made(4,403)(24,299)(2,094)(30,796)
Balance at December 31, 2025$1,153 $72,589 $3,351 $77,093